On June 29, 2026, Tonix Pharmaceuticals Holding Corp. announced the enrollment of the first participant in the HORIZON Study, a Phase 2 clinical trial evaluating TNX-102 SL 5.6 mg as a first-line monotherapy for adults with major depressive disorder. Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutic products for various medical conditions.
